Alessandro Gamboni

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

Paola Ulivi, Elisa Chiadini, Claudio Dazzi et al. · Clinical Lung Cancer · 2015 · 89 citations

Medicine, Molecular Genetics, Oncology +14

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

Giorgio Cocconi, Paolo Carlini, Alessandro Gamboni et al. · Annals of Oncology · 2003 · 65 citations · Full text

Medicine, Oncology, Pharmacology +12

Oxaliplatin in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients With Metastatic Gastric Cancer (MGC)

Luigi Cavanna, Fabrizio Artioli, Claudio Codignola et al. · American Journal of Clinical Oncology · 2006 · 62 citations

Medicine, Oncology, Pharmacology +14

The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Enrico Franceschi, Alicia Tosoni, Santino Minichillo et al. · World Neurosurgery · 2018 · 58 citations · Full text

Medicine, Genetics, Oncology +17